Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
16.17
+1.68 (11.59%)
Dec 20, 2024, 4:00 PM EST - Market closed
Cadrenal Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Selling, General & Admin | 4.92 | 3.55 | 2.52 |
| Research & Development | 3.03 | 4.08 | 0.43 |
| Operating Expenses | 7.95 | 7.63 | 2.95 |
| Operating Income | -7.95 | -7.63 | -2.95 |
| Interest Expense | - | -0.02 | -0.12 |
| Interest & Investment Income | 0.34 | 0.25 | 0 |
| Other Non Operating Income (Expenses) | - | -0.22 | -4.26 |
| EBT Excluding Unusual Items | -7.61 | -7.62 | -7.32 |
| Other Unusual Items | - | -0.74 | - |
| Pretax Income | -7.61 | -8.36 | -7.32 |
| Net Income | -7.61 | -8.36 | -7.32 |
| Net Income to Common | -7.61 | -8.36 | -7.32 |
| Shares Outstanding (Basic) | 1 | 1 | 1 |
| Shares Outstanding (Diluted) | 1 | 1 | 1 |
| Shares Change (YoY) | 40.03% | 70.99% | - |
| EPS (Basic) | -7.06 | -9.29 | -13.92 |
| EPS (Diluted) | -7.06 | -9.29 | -13.92 |
| Free Cash Flow | -6.26 | -3.53 | -1.32 |
| Free Cash Flow Per Share | -5.81 | -3.93 | -2.50 |
| EBITDA | -7.94 | -7.63 | -2.95 |
| D&A For EBITDA | 0 | 0 | 0 |
| EBIT | -7.95 | -7.63 | -2.95 |
Source: S&P Capital IQ. Standard template.
Financial Sources.